BioVasc Revenue and Competitors
Estimated Revenue & Valuation
- BioVasc's estimated annual revenue is currently $310k per year.
- BioVasc's estimated revenue per employee is $155,000
Employee Data
- BioVasc has 2 Employees.
- BioVasc grew their employee count by -71% last year.
BioVasc's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Medical Officer & Managing Partner | Reveal Email/Phone |
BioVasc Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is BioVasc?
BioVasc Inc. is a clinical development consultancy, accelerator and startup incubator for emerging BioPharma | Biotech | Medtech | Nutratech companies. Many biomedical startups are seeking to rapidly obtain robust, meaningful clinical data on their technologies, greatly enhancing their valuations, without breaking the bank (we speak Startups!). Services include protocol development and active study execution for human proof of concept (POC) and first-in-human (FIH) studies, alignment of preclinical and nonclinical studies to support FIH (we speak Science!), coordination with regulatory affairs, business development and other key stakeholders for harmonization of objectives, execution of active phase clinical studies, and safety and medical monitoring of human studies (we speak Clinical!).
keywords:N/AN/A
Total Funding
2
Number of Employees
$310k
Revenue (est)
-71%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.1M | 2 | 0% | N/A |
#2 | $0.2M | 2 | 0% | $138M |
#3 | $128.2M | 2 | 0% | $138.2M |
#4 | $0M | 2 | 0% | $2.6M |
#5 | $0M | 2 | 0% | $3M |